Alzheimers Research & Therapy

Article	Citations
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	208
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	162
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	161
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	152
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	148
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	133
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	133
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	113
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	109
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	104
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	92
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	90
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	89
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	89
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	87
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	85
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	85
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	81
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	79
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	78
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	77
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	73
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	72
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	71
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	70

Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	68
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	68
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	66
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	66
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	65
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	64
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	61
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	60
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	60
Genome-wide association studies of Alzheimer’s disease and related disorders stratified by sex, onset age, and Apolipoprotein E genotype reveal novel risk loci in African Americans	60
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	58
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	58
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	57
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	56
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	56
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	56
Serum neurofilament light chain level as a predictor of cognitive stage transition	56
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	53
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis	53
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	53
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	53
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	51
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	50
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	50
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	49
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	49
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	47
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	46
The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP	45
Ap1s1 reduction in the aging brain heightens neuronal vulnerability to amyloid-β and oxidative stress in Alzheimer’s pathogenesis	44
The role of structural and functional parameters in designing pathology-specific tDCS protocols for primary progressive aphasia	44
Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders	43
Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort	43
Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease	42
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	42
Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease	42
Polygenic pathways shape white matter vulnerability to Alzheimer’s disease-related pathophysiological changes	42
Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease	41
An improved immunoassay detects Aβ oligomers in human biofluids: their CSF levels rise with tau and phosphotau levels	41
Generalizable MRI normative modelling to detect age-inappropriate neurodegeneration	41
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach	40
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease	39
The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults	39
Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?	39
Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study	39
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study	38
Quantification of identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy with machine learning: a post hoc analysis of a diagnostic trial and validation of a	38
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individ	38
Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology	38
Perivascular space enlargement accelerates in ageing and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study	37

White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia	37
Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer’s continuum	36
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity	36
Sex-specific risk factors and clinical dementia outcomes for white matter hyperintensities in a large South Korean cohort	35
Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia	34
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	34
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies	32
Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study	32
Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI	32
Disruption of electrophysiological rhythms and memory impairment in an Alzheimer’s transgenic rat model	32
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology	32
The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer’s disease	32
Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project	31
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease	31
Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change	31
Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort	30
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease	30
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease: a natural language processing study	30
The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study	30
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases	30
Longitudinal characteristics of plasma biomarkers in Chinese older adults with Alzheimer’s disease	29
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2	29
Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer	29
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxy	29
Social frailty and its association with cognitive trajectories in older adults: a prospective cohort study	29
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia	29
18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	29
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease	28
Dementia with Lewy bodies and gait neural basis: a cross-sectional study	28
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline	28
Associations of resting heart rate with incident dementia, cognition, and brain structure: a prospective cohort study of UK biobank	28
Synaptic protein CSF levels relate to memory scores in individuals without dementia	28
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration	28
Distinct effects of blood pressure parameters on Alzheimer’s and vascular markers in 1,952 Asian individuals without dementia	28
Nanoscale alterations in GABAB receptors and GIRK channel organization on the hippocampus of APP/PS1 mice	28
Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis	28
Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils	28
Letter to the Editor Authors’ Response: Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	27
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals	27
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform	27
Multi-omics analyses identify gut microbiota-fecal metabolites-brain-cognition pathways in the Alzheimer’s disease continuum	27
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disea	27
Rescue of protein dyshomeostasis in hippocampal astrocytes from an Alzheimer’s disease mouse model by stabilizing ER-mitochondrial interactions at a 20 nm distance	27
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	27
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease	26
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model	26
Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients	26
Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data	26
Towards a national registry for Alzheimer’s disease and related dementias: rationale, design, and initial observations of the ABOARD cohort	26
REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals	26
Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals	26
Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort	26
Cognitive impairment indicator for the neuropsychological test batteries in the Canadian Longitudinal Study on Aging: definition and evidence for validity	26
Association of midlife body-weight variability and cycles with earlier dementia onset: a nationwide cohort study	26
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database	25
Quantitative estimate of cognitive resilience and its medical and genetic associations	25
Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer’s disease	25
A longitudinal study of the 5xFAD mouse retina delineates Amyloid beta (Aβ)-mediated retinal pathology from age-related changes	25
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data	25
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease	25
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis	25
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials	25
Potential role of Amyloid-β on the association between Orexin-A and blood-brain barrier leakage of globus pallidus in Alzheimer’s disease and dementia with lewy bodies	25
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease	24
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease	24
Subclinical carotid artery atherosclerosis and cognitive function in older adults	24
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment	24
Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults	24
β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis	24
Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice	23
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology	23
Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia	23
The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study	23
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study	23
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	23
Correction to: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis	23
Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease	23
Long-term retrieval performance is associated with CA1 hippocampal volume in older adults and individuals at risk for dementia	23
Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats	23
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease	23

Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning	23
Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment	23
First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population	23
A polygenic risk score for Alzheimer’s disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S.	23
Sex differences in Alzheimer’s disease CSF biomarkers and their association with Aβ pathology on PET in cognitively unimpaired individuals	23
Purpose in life promotes resilience to age-related brain burden in middle-aged adults	22
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment	22
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies	22
Methodological quality of systematic reviews on treatments for Alzheimer’s disease: a cross-sectional study	22
Apolipoprotein E and sex modulate fatty acid metabolism in a prospective observational study of cognitive decline	22
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein	22
Circular RNA APP contributes to Alzheimer’s disease pathogenesis by modulating microglial polarization via miR-1906/CLIC1 axis	22
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy	22
The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment	22
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	21
The course of primary progressive aphasia diagnosis: a cross-sectional study	21
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	21
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease	21
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	21
Anticipatory reaching motor behavior characterizes patients within the Alzheimer’s disease continuum in a virtual reality environment	21
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	21
Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease	21
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	21
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	20
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	20
Optimizing midlife metabolic syndrome thresholds for dementia: a prospective study of two UK population-based cohorts	20
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	20
Diabetes status, duration, and risk of dementia among ischemic stroke patients	20
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	20
An accessible and efficient mobile eye-tracking application for community-based cognitive impairment screening in China	20
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis	20
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	20
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	20
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	19
Correction: Abdominal obesity and the risk of young-onset dementia in women: a nationwide cohort study	19
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	19
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	19
Insomnia, early and late rising are associated with small hippocampal volume and large white matter hyperintensity burden	19
Frontotemporal structure preservation underlies the protective effect of lifetime intellectual cognitive reserve on cognition in the elderly	19
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort	19
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort	19
Neurobiological correlates of Mild Behavioral Impairment: a systematic review and meta-analysis	19
Correction: Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I‑UDSNB 1.0): development and normative data	19
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review	19
Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease	19
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	19
Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease	18
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	18
Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss	18
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	18
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer’s disease	18
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	18
Hampered AMPK-ULK1 cascade in Alzheimer’s disease (AD) instigates mitochondria dysfunctions and AD-related alterations which are alleviated by metformin	18
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk	18
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	18
Subjective cognitive decline predicts longitudinal neuropsychological test performance in an unsupervised online setting in the Brain Health Registry	18
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status	18
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	18
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging	18
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217	18
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways	18
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns	18
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults	17
Network dynamics-based subtyping of Alzheimer’s disease with microglial genetic risk factors	17
Response to Schmidt et al.: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	17
Biophysical models applied to dementia patients reveal links between geographical origin, gender, disease duration, and loss of neural inhibition	17
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact	17
Development and validation of a novel predictive model for dementia risk in middle-aged and elderly depression individuals: a large and longitudinal machine learning cohort study	17
Rotation errors in path integration are associated with Alzheimer’s disease tau pathology: a cross-sectional study	17
White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition	17
Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status	17
Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study	17
Amyloid-PET imaging predicts functional decline in clinically normal individuals	17
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy	17
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	17
Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer’s disease	17
Correction: Diagnostic performance of plasma pTau217, pTau181, Aβ1‑42 and Aβ1‑40 in the LUMIPULSE automated platform for the detection of Alzheimer disease	17
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic	17
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease	17
Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review	17
Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status	16
Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease	16
Deep-learning based multi-modal models for brain age, cognition and amyloid pathology prediction	16
Intracranial internal carotid artery calcification is not predictive of future cognitive decline	16
Stress, depression, and risk of dementia – a cohort study in the total population between 18 and 65 years old in Region Stockholm	16
Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial	16
Associations of computer gaming with incident dementia, cognitive functions, and brain structure: a prospective cohort study and Mendelian randomization analysis	16
Identification of profiles associated with conversions between the Alzheimer’s disease stages, using a machine learning approach	16
Herpesviruses, antiviral treatment, and the risk of dementia – systematic review and meta-analysis	16
Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites	16
Is later-life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post-mortem human brain tissue?	16
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab	16
Association between retinal microvascular abnormalities and late-life brain amyloid-β deposition: the ARIC-PET study	16
Combined effects of physical activity, cognitive activity, and dietary patterns on cognitive impairment in older adults with consideration of APOE genotype: a cohort study	16
Herpes zoster and long-term risk of subjective cognitive decline	16